Despite the availability of effective treatments, diseases like HIV and measles are seeing resurgences. (Credit: Corona Borealis Studio/Shutterstock)
NEW ORLEANS — In the ongoing battle against HIV, researchers have made a groundbreaking discovery that could pave the way for eliminating the virus from one of its most stubborn hiding places – the brain. A recent study published in the journal Brain has shown promising results in reducing the amount of an HIV-like virus in the brains of infected monkeys using a novel drug approach.
HIV, the virus that causes AIDS, has long been known to invade the brain, leading to cognitive problems in many patients even when the virus is well-controlled in the rest of the body. This is because the brain acts as a sanctuary for the virus, protected by the blood-brain barrier, which prevents many drugs from entering. As a result, HIV can persist in the brain even when it’s undetectable in the blood, causing inflammation and damage over time.
Enter BLZ945, a drug originally developed to fight brain tumors. This medication targets a specific protein called CSF1R, which is found in high levels on certain immune cells in the brain, particularly those known as perivascular macrophages. These cells act as viral reservoirs, harboring HIV and allowing it to persist despite treatment.
In this groundbreaking study, researchers infected rhesus monkeys with SIV, a close relative of HIV that affects primates. They then treated some of the monkeys with BLZ945 for about a month. The results were striking – the drug significantly reduced the number of infected cells in multiple brain regions, in some cases by up to 99%.
“This research is an important step in tackling brain-related issues caused by HIV, which still affect people even when they are on effective HIV medication,” says lead study author Woong-Ki Kim, PhD, the associate director for research at Tulane National Primate Research Center, in a university release. “By specifically targeting the infected cells in the brain, we may be able to clear the virus from these hidden areas, which has been a major challenge in HIV treatment.”
What makes this finding so exciting is that it offers a potential new strategy for tackling HIV in the brain. Current HIV treatments, while effective at controlling the virus in the blood, often struggle to penetrate the brain’s defenses. BLZ945, however, is designed to cross the blood-brain barrier, allowing it to directly target the infected cells hiding within.
The drug works by essentially cutting off the lifeline of these infected cells. By blocking CSF1R, BLZ945 causes the death of perivascular macrophages, which are the main target of HIV in the brain. Importantly, the drug seemed to spare other crucial brain cells, including microglia, which play important roles in brain health.
This selective targeting is crucial, as it suggests that BLZ945 could potentially clear HIV from the brain without causing widespread damage to healthy brain tissue. This is a delicate balance that has been difficult to achieve with other approaches.
If these results can be replicated in humans, it could lead to new treatments that not only control HIV but potentially eliminate it from one of its most persistent hiding places. This could be particularly beneficial for the many HIV patients who suffer from cognitive problems, known collectively as HIV-associated neurocognitive disorder (HAND).
However, it’s important to note that this is still early-stage research. While the results in monkeys are promising, much more work needs to be done before this approach can be tested in humans. Nevertheless, this study represents a significant step forward in our understanding of how to tackle HIV in the brain, offering new hope for improved treatments in the future.
Paper Summary
Methodology
The researchers used 12 rhesus monkeys in their study. Nine of these monkeys were infected with SIV, a virus similar to HIV. Three of the infected monkeys were left untreated as a control group. The other six infected monkeys were split into two groups: one group received a low dose of the drug BLZ945, while the other received a high dose.
The drug was given orally every day for 20-30 days. After this treatment period, the researchers examined the brains of all the monkeys, looking at the number of certain types of immune cells and the amount of virus present in different brain regions.
Key Results
BLZ945 significantly reduced the number of perivascular macrophages (a type of immune cell) in the brain, especially at the higher dose. The drug did not seem to affect microglia, another type of brain immune cell.
In most brain regions examined, the amount of viral DNA was reduced by 95-99% in the treated monkeys compared to the untreated ones. The reduction in viral DNA correlated with the decrease in perivascular macrophages, suggesting these cells were the main source of the virus in the brain. The drug did not appear to affect the amount of virus in the blood or cerebrospinal fluid.
Study Limitations
This study had a small sample size and short duration. Only 12 monkeys were used, with just 3 in each treatment group. The treatment was only given for 20-30 days, which may not be long enough to see all potential effects or side-effects.
While SIV is similar to HIV, there may be differences in how the viruses behave in the brain. Also, results in monkeys don’t always translate directly to humans.
Discussion & Takeaways
The researchers concluded that BLZ945 shows promise as a potential treatment for eliminating HIV from the brain. By targeting CSF1R, the drug selectively depletes the cells that harbor the virus without causing widespread damage to other brain cells. This approach could potentially be combined with current HIV treatments to more effectively combat the virus throughout the body.
However, the authors emphasize that more research is needed. Future studies will need to look at longer treatment periods, potential side effects, and whether the virus could develop resistance to this approach. They also plan to test the drug in monkeys with chronic SIV infection who are already on antiretroviral therapy, which would more closely mimic the situation in most HIV patients.
If further research continues to show promise, this approach could eventually lead to clinical trials in humans. The ultimate goal would be to develop a treatment that could not only control HIV but potentially eliminate it from its hiding places in the body, including the brain. This could have significant implications for reducing the long-term health impacts of HIV infection, particularly on brain function.
